

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 42

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

13-13144-02

5-76967

<p>Licensee</p> <p>1. Franciscan Alliance, Inc., d/b/a Franciscan St. Anthony Health – Michigan City</p> <p>2. 301 West Homer St. Michigan City, IN 46360</p>	<p>In accordance with letter dated February 8, 2012,</p> <p>3. License number 13-13144-02 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date January 31, 2016</p> <hr/> <p>5. Docket No. 030-09928 Reference No.</p>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 Curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (3M Model Series 6500 and 6520, Medi-Physics, Model 6711 and Bard Brachytherapy, Inc., Model STM 1251)	D. 2 Curies
E. Uranium depleted in Uranium-235	E. Cadmium plated metal	E. 105 kilograms

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
 - D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
 - E. Shielding in a linear accelerator.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-13144-02

Docket or Reference Number
030-09928

Amendment No. 42

CONDITIONS

10. Location(s) of Use: 301 West Homer Street, Michigan City, Indiana, and **8955 W. 400 North, Michigan City, Indiana.**
11. Radiation Safety Officer: Richard L. Dobben, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Richard Dobben, M.D.	10 CFR 35.100, 35.200, and 35.300 (iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma therapy).
Mir J. Shah, M.D.	10 CFR 35.400.
Sridhar R. Mothkur, M.D.	10 CFR 35.100, 35.200, and 35.300 (excluding iodine-131 for thyroid carcinoma therapy).
Jagannath K. Dixit, M.D.	10 CFR 35.100, 35.200, and 35.300 (iodine-131 for treatment of hyperthyroidism and cardiac dysfunction).
David P. Megremis, D.O.	10 CFR 35.100, 35.200, and 35.300.
Sea Chen, M.D.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 and the parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV).

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-13144-02Docket or Reference Number
030-09928**Amendment No. 42**

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.


- A. Application dated October 17, 2005; and
- B. Letters dated December 27, 2005, February 4, 2009 except item 4, February 14, 2011, **February 8, 2012**, and **May 4, 2012**.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

MAY 15 2012

By



Toye L. Simmons
Materials Licensing Branch
Region III